Literature DB >> 3535659

In vitro and pharmacokinetic properties of the carbapenems.

R Wise.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3535659      PMCID： PMC180556          DOI： 10.1128/AAC.30.3.343

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  31 in total

1.  N-Acetimidoyl- and N-formimidoylthienamycin derivatives: antipseudomonal beta-lactam antibiotics.

Authors:  W J Leanza; K J Wildonger; T W Miller; B G Christensen
Journal:  J Med Chem       Date:  1979-12       Impact factor: 7.446

2.  Asparenomycin A, a new carbapenem antibiotic.

Authors:  K Tanaka; J Shoji; Y Terui; N Tsuji; E Kondo; M Mayama; Y Kawamura; T Hattori; K Matsumoto; T Yoshida
Journal:  J Antibiot (Tokyo)       Date:  1981-07       Impact factor: 2.649

3.  N-formimidoyl-thienamycin a novel beta-lactam: an in-vitro comparison with other beta-lactam antibiotics.

Authors:  R Wise; J M Andrews; N Patel
Journal:  J Antimicrob Chemother       Date:  1981-05       Impact factor: 5.790

4.  PS-5, a new beta-lactam antibiotic from Streptomyces.

Authors:  K Okamura; S Hirata; Y Okumura; Y Fukagawa; Y Shimauchi; K Kouno; T Ishikura
Journal:  J Antibiot (Tokyo)       Date:  1978-05       Impact factor: 2.649

5.  In vitro activity of thienamycin.

Authors:  F P Tally; N V Jacobus; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

6.  Carpetimycins A and B, new beta-lactam antibiotics.

Authors:  M Nakayama; A Iwasaki; S Kimura; T Mizoguchi; S Tanabe; A Murakami; I Watanabe; M Okuchi; H Itoh; Y Saino; F Kobayashi; T Mori
Journal:  J Antibiot (Tokyo)       Date:  1980-11       Impact factor: 2.649

7.  PS-6 and PS-7, new beta-lactam antibiotics. Isolation, physicochemical properties and structures.

Authors:  N Shibamoto; A Koki; M Nishino; K Nakamura; K Kiyoshima; K Okamura; M Okabe; R Okamoto; Y Fukagawa; Y Shimauchi; T Ishikura; J Lein
Journal:  J Antibiot (Tokyo)       Date:  1980-10       Impact factor: 2.649

8.  Comparative antibacterial properties in vitro of seven olivanic acid derivatives: MM 4550, MM 13902, MM 17880, MM 22380, MM 22381, MM 22382 and MM 22383.

Authors:  M J Basker; R J Boon; P A Hunter
Journal:  J Antibiot (Tokyo)       Date:  1980-08       Impact factor: 2.649

9.  MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities.

Authors:  H Kropp; J G Sundelof; J S Kahan; F M Kahan; J Birnbaum
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

10.  Olivanic acids, a family of beta-lactam antibiotics with beta-lactamase inhibitory properties produced by Streptomyces species. II. Isolation and characterisation of the olivanic acids MM 4550, MM 13902 and MM 17880 from Streptomyces olivaceus.

Authors:  J D Hood; S J Box; M S Verrall
Journal:  J Antibiot (Tokyo)       Date:  1979-04       Impact factor: 2.649
View more
  10 in total

1.  Multicenter in vitro evaluation of SM-7338, a new carbapenem.

Authors:  R N Jones; K E Aldridge; S D Allen; A L Barry; P C Fuchs; E H Gerlach; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

2.  Renal dehydropeptidase-I stability of LJC 10,627, a new carbapenem antibiotic.

Authors:  M Hikida; K Kawashima; K Nishiki; Y Furukawa; K Nishizawa; I Saito; S Kuwao
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

3.  In vitro and in vivo activities of LJC10,627, a new carbapenem with stability to dehydropeptidase I.

Authors:  P J Petersen; N V Jacobus; W J Weiss; R T Testa
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

4.  In vitro activity and beta-lactamase stability of a new carbapenem, SM-7338.

Authors:  H C Neu; A Novelli; N X Chin
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

5.  Meropenem pharmacokinetics and penetration into an inflammatory exudate.

Authors:  R Wise; M Logan; M Cooper; J P Ashby; J M Andrews
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

Review 6.  Meropenem clinical pharmacokinetics.

Authors:  J W Mouton; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

7.  Antimicrobial activity of the new carbapenem biapenem compared to imipenem, meropenem and other broad-spectrum beta-lactam drugs.

Authors:  H S Sader; R N Jones
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-05       Impact factor: 3.267

8.  Identification and characterization of the carbapenem MM 4550 and its gene cluster in Streptomyces argenteolus ATCC 11009.

Authors:  Rongfeng Li; Evan P Lloyd; Kristos A Moshos; Craig A Townsend
Journal:  Chembiochem       Date:  2014-01-13       Impact factor: 3.164

9.  Sequential, single-dose pharmacokinetic evaluation of meropenem in hospitalized infants and children.

Authors:  J L Blumer; M D Reed; G L Kearns; R F Jacobs; W M Gooch; R Yogev; K Willims; B J Ewing
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

10.  Imipenem/cilastatin encapsulated polymeric nanoparticles for destroying carbapenem-resistant bacterial isolates.

Authors:  Mona I Shaaban; Mohamed A Shaker; Fatma M Mady
Journal:  J Nanobiotechnology       Date:  2017-04-11       Impact factor: 10.435
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.